<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484328</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-07-3-007</org_study_id>
    <nct_id>NCT00484328</nct_id>
  </id_info>
  <brief_title>Ribavirin, Its Dosing Regime</brief_title>
  <acronym>Ribados</acronym>
  <official_title>Ribavirin, Its Dosing Regime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the medicines for chronic hepatitis C can be
      taken once daily, instead of twice daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment of patients with chronic hepatitis C infection (HCV) is treatment with
      ribavirin. Actually, the compliance (2x daily) seems to be a problem. To increase patients'
      compliance, it is investigated if the total dose of ribavirin can be taken once daily.

      The pharmacokinetics of ribavirin at different dosage regimes is investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pharmacokinetics of ribavirin at different dosage regimes, measured by the area under the curve of the concentration-time graph</measure>
    <time_frame>within 24 weeks after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The tolerability of the treatment at different dosage regimes of ribavirin</measure>
    <time_frame>24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The antioxidant capacity in plasma and erythrocytes at different dosing regimes</measure>
    <time_frame>24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of ribavirin on the hemolysis</measure>
    <time_frame>24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of ribavirin in erythrocytes in the different dosing regimes</measure>
    <time_frame>24 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>different dosing regimes of Ribavirin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  anti-HCV positivity &gt; 6 months

          -  Positive HCV-RNA genotype 1 or 4

          -  Liver biopsy within one year before the start of therapy

          -  Intention to be treated and participate treatment

          -  body weight at or above 75 kg

        Exclusion Criteria:

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aalt Bast, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2007</study_first_submitted>
  <study_first_submitted_qc>June 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2007</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <name_title>Prof. A.Bast</name_title>
    <organization>Maastricht University</organization>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Dosage</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

